Vanguard Group Inc. Purchases 708,095 Shares of Celldex Therapeutics, Inc. (CLDX)

Vanguard Group Inc. raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 7.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,774,858 shares of the biopharmaceutical company’s stock after acquiring an additional 708,095 shares during the quarter. Vanguard Group Inc. owned 7.81% of Celldex Therapeutics worth $24,143,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Northern Trust Corp grew its position in Celldex Therapeutics by 12.2% in the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock valued at $4,992,000 after acquiring an additional 219,661 shares in the last quarter. Nationwide Fund Advisors grew its position in Celldex Therapeutics by 3.5% in the second quarter. Nationwide Fund Advisors now owns 111,757 shares of the biopharmaceutical company’s stock valued at $276,000 after acquiring an additional 3,742 shares in the last quarter. Overbrook Management Corp acquired a new stake in Celldex Therapeutics in the second quarter valued at approximately $139,000. Ameriprise Financial Inc. acquired a new stake in Celldex Therapeutics in the second quarter valued at approximately $943,000. Finally, TIAA CREF Investment Management LLC grew its position in Celldex Therapeutics by 22.6% in the second quarter. TIAA CREF Investment Management LLC now owns 314,485 shares of the biopharmaceutical company’s stock valued at $777,000 after acquiring an additional 57,909 shares in the last quarter. 53.06% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.thestockobserver.com/2017/11/14/vanguard-group-inc-purchases-708095-shares-of-celldex-therapeutics-inc-cldx.html.

Shares of Celldex Therapeutics, Inc. (NASDAQ CLDX) opened at $2.74 on Tuesday. Celldex Therapeutics, Inc. has a 1 year low of $2.20 and a 1 year high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.07. The firm had revenue of $3.90 million during the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The firm’s revenue was up 77.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.29) earnings per share. equities research analysts predict that Celldex Therapeutics, Inc. will post -0.97 earnings per share for the current year.

Several analysts have issued reports on CLDX shares. Zacks Investment Research downgraded shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, August 1st. ValuEngine downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $9.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $6.31.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply